Celldex Therapeutics, Inc. Stock Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 2.48B 2.19B 2.07B 1.87B 3.53B 238B 3.57B 24.8B 9.54B 122B 9.33B 9.13B 390B | P/E 2026 * |
-7.54x | P/E 2027 * | -7.41x |
|---|---|---|---|---|---|
| Enterprise Value | 1.82B 1.6B 1.52B 1.37B 2.59B 175B 2.62B 18.19B 7B 89.33B 6.84B 6.69B 286B | EV / Sales 2026 * |
985x | EV / Sales 2027 * | 186x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 2014-07-29 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 2008-08-31 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 2009-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 2008-11-30 |
Harry Penner
CHM | Chairman | 80 | 2025-06-04 |
Herbert Conrad
BRD | Director/Board Member | 93 | 2008-02-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 2.48B | |
| +4.16% | -0.30% | +58.96% | +94.17% | 71.53B | |
| -0.19% | +1.32% | +37.20% | +81.33% | 60.12B | |
| -1.51% | +2.39% | +9.10% | +36.79% | 48.85B | |
| +0.66% | +1.20% | +42.71% | +39.81% | 44.28B | |
| +1.52% | +8.92% | +344.86% | +693.85% | 43.83B | |
| +1.82% | +1.81% | +9.07% | +108.18% | 41.53B | |
| -0.67% | -0.45% | +4.47% | +46.37% | 30.13B | |
| +4.77% | +6.46% | +41.54% | +22.78% | 27.98B | |
| +0.58% | -1.91% | -19.39% | +357.57% | 25.25B | |
| Average | +2.24% | +0.48% | +58.73% | +164.54% | 43.72B | |
| Weighted average by Cap. | +1.41% | +0.63% | +63.76% | +155.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.85M 1.63M 1.54M 1.39M 2.63M 177M 2.66M 18.47M 7.11M 90.68M 6.95M 6.79M 291M | 9.95M 8.77M 8.31M 7.5M 14.13M 954M 14.31M 99.37M 38.24M 488M 37.38M 36.56M 1.56B |
| Net income | -319M -281M -266M -240M -453M -30.6B -459M -3.19B -1.23B -15.64B -1.2B -1.17B -50.16B | -361M -318M -301M -272M -512M -34.61B -519M -3.6B -1.39B -17.69B -1.36B -1.33B -56.72B |
| Net Debt | -662M -583M -553M -499M -940M -63.51B -952M -6.61B -2.54B -32.47B -2.49B -2.43B -104B | -633M -558M -529M -477M -899M -60.74B -911M -6.32B -2.43B -31.05B -2.38B -2.33B -99.55B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
